Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
44 participants
INTERVENTIONAL
2016-08-31
2023-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The aim of this study is to determine how different parameters affect the efficacy of the treatment. This is a prospective double-blinded randomized controlled trial comparing two groups, the experimental group using 1250 mW for 4 seconds and the control group using 2000 mW for 2 seconds.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Endoscopic Cyclophotocoagulation in Normal Tension Glaucoma
NCT04651530
Safety Study of Conventional Versus Micropulse Transscleral Cyclophotocoagulation in Treating End-Stage Glaucoma
NCT00349414
Comparative Effectiveness and Tolerance of Subliminal Subthreshold Transscleral Cyclophotocoagulation
NCT03961035
How Safe and Effective is Micropulse Transscleral Cyclophotocoagulation in Patients With Uncontrolled Glaucoma?
NCT02627352
Treatment Outcomes of MicroPulse Trans-scleral Cyclophotocoagulation in Uncontrolled Glaucoma
NCT03187418
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Diode laser using conventional settings
The cyclophotocoagulation protocol is used with the conventional cyclophotocoagulation settings of 2000 mW for 2 seconds.
Cyclophotocoagulation protocol
* Intravenous route is installed
* Retrobulbar anaesthesia : 50% xylocaine (2%) + 50% bupivicaine
* Parameters set for laser treatment (1250mW-4seconds or 2000mW-2 seconds depending on the assigned group)
* Pars plana measurement using transillumination (if needed)
* Laser treatment applied approximately 1mm post to limbus
* Dexamethasone 0,5 mg subconjunctival injection
* Post-op regimen: Prednisolone 1% qid x 4 weeks, Atropine 1% bid x 2 weeks + Erythromycin ointment + patch x 6h
Conventional cyclophotocoagulation
1250 mW for 4 seconds.
Diode laser using modified settings
The cyclophotocoagulation protocol is used with the modified cyclophotocoagulation settings of 1250 mW for 4 seconds.
Cyclophotocoagulation protocol
* Intravenous route is installed
* Retrobulbar anaesthesia : 50% xylocaine (2%) + 50% bupivicaine
* Parameters set for laser treatment (1250mW-4seconds or 2000mW-2 seconds depending on the assigned group)
* Pars plana measurement using transillumination (if needed)
* Laser treatment applied approximately 1mm post to limbus
* Dexamethasone 0,5 mg subconjunctival injection
* Post-op regimen: Prednisolone 1% qid x 4 weeks, Atropine 1% bid x 2 weeks + Erythromycin ointment + patch x 6h
Modified cyclophotocoagulation
2000 mW for 2 seconds.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Cyclophotocoagulation protocol
* Intravenous route is installed
* Retrobulbar anaesthesia : 50% xylocaine (2%) + 50% bupivicaine
* Parameters set for laser treatment (1250mW-4seconds or 2000mW-2 seconds depending on the assigned group)
* Pars plana measurement using transillumination (if needed)
* Laser treatment applied approximately 1mm post to limbus
* Dexamethasone 0,5 mg subconjunctival injection
* Post-op regimen: Prednisolone 1% qid x 4 weeks, Atropine 1% bid x 2 weeks + Erythromycin ointment + patch x 6h
Conventional cyclophotocoagulation
1250 mW for 4 seconds.
Modified cyclophotocoagulation
2000 mW for 2 seconds.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Cyclophotocoagulation necessary to prevent visual loss
* Cyclophotocoagulation necessary to prevent or to reduce ocular discomfort
Exclusion Criteria
* Patients receiving concomitant treatment the same day as the intervention
* Patient not able to follow the prescribed post-operative treatment
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
CHU de Quebec-Universite Laval
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Andrew Toren, Doctor
Role: PRINCIPAL_INVESTIGATOR
Centre de recherche du CHU de Québec : Université Laval
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Centre universitaire d'ophtalmologie, Hôpital du Saint-Sacrement. CHU de Québec
Québec, , Canada
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2015-2212
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.